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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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Given the unprecedented interest from biopharmaceutical firms and broadening
range of approaches to attacking the disease, the need for the Huntington’s disease
community to participate in research studies and clinical trials is “exploding,”
CHDI’s head scientist said at the organization’s 14th Annual HD Therapeutics
Conference yesterday.
“This is not a time to rest on our laurels,” said Robert Pacifici, Ph.D., the chief
scientific officer for CHDI Foundation, Inc., the nonprofit virtual biotech
dedicated to finding HD treatments. “Trials won’t go forward without people
willing to take the risk of taking a drug never taken before.”
Dr. Pacifici’s comments came in an interview with me at the conference venue,
the Parker Palm Springs hotel in Palm Springs, CA. The gathering of scientists,
pharma executives, and advocates ends today.
Critical new research studies
The conference comes just after news of the start of Roche’s historic Phase 3
gene-silencing clinical trial and other clinical trial programs (click here to read
more).
“It’s exciting times,” Dr. Pacifici observed. “Now more than ever we need to
make sure that these channels of communication between patients and caregivers
and researchers remain open and clear so that everybody knows what’s going on.”

► 2013 (30)
► 2012 (26)
► 2011 (33)
► 2010 (26)
► 2009 (21)
► 2008 (7)
► 2007 (7)
► 2006 (4)
► 2005 (17)

About Me
GENE VERITAS

View my complete profile

HD Links
Huntington's Disease Society
of America

With the advent of more trials, both the pace and number of research projects
requiring volunteers is growing rapidly, he explained. One involves a forthcoming
brain imaging study (using a PET-ligand).
To help understand the disease and measure the effect of potential drugs in clinical
trials, scientists need to find more biomarkers (signals of the disease) in humans.
For years, they have collected samples of blood. More recently, they started
examining the cerebrospinal fluid and saliva.
Now CHDI wants to collect semen, Dr. Pacifici said. “There are certain things that
happen only in those cell types that are going tell us what happens to Huntington’s
DNA, and that’s going to be really critical for our efforts as well,” he explained.
CHDI will also establish a “Brains for HD” initiative to request donations of that
organ from deceased individuals, Dr. Pacifici added. “Invaluable,” he said of the
importance of brains in HD research. “Especially the rare young brain, if
somebody happens to pass away from something else, and we can harvest the
brain before it experiences the ravages of Huntington’s disease.”
You can watch my interview with Dr. Pacifici in the video below.
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Not a time for the Huntington's community to rest on its laurels from Gene Veritas
on Vimeo.
‘Huntington’s homework’
Dr. Pacifici outlined the conference’s three major areas of focus.
He described the first as “Huntington’s homework.”
“We might not like it, and it might be tough, and it requires some dedication, but
we still have basic research to do to understand the underlying pathophysiology of
Huntington’s,” he explained. “There are still some fundamental questions about
what’s broken in HD that we need to understand, because until you understand
what’s broken, it’s hard to fix it.”
To that end, this year’s conference talks have included topics such as HD’s
hampering of the brain’s ability to repair itself and the loss of white matter in
presymptomatic gene carriers like me.
Modifier genes: a key discovery
A second area involves the discovery of so-called modifier genes – a major
advance only made possible with the participation in the research of 9,000 HD
family members.
“We now know there are other genetic factors that influence, for any given CAG
[the length of the genetic coding for the huntingtin gene], whether you’ll get the
disease sooner or later,” Dr. Pacifici noted.
People with same gene length can get the disease decades earlier or later, he said.
“That’s a really big range, and what we’ve found is that the propensity to get it
earlier or later is also heritable.”
The modifier genes affect onset by as much as a dozen years or more, he added.
“Imagine if we could make a drug that did the same thing – or did it even better,”
Dr. Pacifici said. CHDI and HD scientists are at work on this task.
‘A wonderful time for HD research’
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A third major aspect of the conference concerns “genetically identified targets”
that are changed in people because of HD. This type of lab research is still in the
early stages, Dr. Pacifici observed. However, these targets might also serve as
models for drug design.
Dr. Pacifici noted that in the relatively mature field of “huntingtin lowering” – the
approach of the Roche drug and of several other companies present at the
conference – something “unthinkable” five years ago has occurred: the possibility
of a “small molecule” drug. Such a drug would be taken orally, thus avoiding the
spinal taps and other highly invasive procedures currently envisioned for these
drugs.
On February 26, Anuradha Bhattacharyya, Ph.D., of Ireland- and U.S.-based PTC
Therapeutics presented a paper on the company’s efforts to develop such a drug.
As a nonprofit, CHDI’s job is to provide all firms access to the necessary
biotechnological tools they need and to potential volunteers for studies and trials,
Dr. Pacifici said. CHDI has spent hundreds of millions of dollars in the effort to
treat HD, including grants to scientists and companies.
He concluded: “It’s a wonderful time to be a researcher in the area of
Huntington’s drug discovery and it will soon be an opportune time to engage the
broader patient community, because we really need your help.”
(Future articles will discuss other aspects of the meeting. For additional coverage,
visit HDBuzz.net.)
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